Literature DB >> 2565464

Minocycline for dystrophic epidermolysis bullosa.

J E White.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2565464     DOI： 10.1016/s0140-6736(89)92555-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential.

Authors:  K Suomalainen; T Sorsa; L M Golub; N Ramamurthy; H M Lee; V J Uitto; H Saari; Y T Konttinen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

3.  Proteases, dermal proliferation, keratinization and calcium.

Authors:  D P MacLeod
Journal:  J R Soc Med       Date:  1990-04       Impact factor: 18.000

4.  Positive influence of tetracycline on human fetal kidney in serum-free organ culture.

Authors:  N Brière; P Chailler
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-04       Impact factor: 2.416

5.  Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation.

Authors:  Hanumanth K Reddy; Imam E Tjahja; Scott E Campbell; Joseph S Janicki; Melvin R Hayden; Suresh C Tyagi
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

6.  Chemically modified tetracyclines: Novel therapeutic agents in the management of chronic periodontitis.

Authors:  Rupali Agnihotri; Sumit Gaur
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

Review 7.  Periodontal therapeutics: Current host-modulation agents and future directions.

Authors:  Lorne M Golub; Hsi-Ming Lee
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 12.239

Review 8.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.